DNTH · CIK 0001690585 · operating
Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing complement-targeted therapies for severe autoimmune and inflammatory diseases. The company's lead candidate, DNTH103, is a human monoclonal antibody designed to bind the active form of C1s with picomolar affinity. DNTH103 is currently in clinical trials for generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
The company operates as a clinical-stage entity and has not generated product revenues. As of its most recent reporting, Dianthus maintains operations primarily in its New York headquarters with a team of 78 full-time employees. The company was founded in 2019 and is incorporated in Delaware, with shares trading on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.55 | $-2.55 | +69.8% | |
| 2023 | $-8.45 | $-8.45 | -555.0% | |
| 2022 | $-1.29 | $-1.29 | +0.0% | |
| 2021 | $-1.29 | $-1.29 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-11 | 0000950170-25-037131 | SEC ↗ |
| 2023-12-31 | 2024-03-21 | 0000950170-24-034681 | SEC ↗ |
| 2022-12-31 | 2023-03-23 | 0000950170-23-009331 | SEC ↗ |
| 2021-12-31 | 2022-03-08 | 0001193125-22-068759 | SEC ↗ |
| 2020-12-31 | 2021-03-03 | 0001193125-21-066707 | SEC ↗ |
| 2019-12-31 | 2020-03-03 | 0001193125-20-059835 | SEC ↗ |
| 2018-12-31 | 2019-03-19 | 0001193125-19-078948 | SEC ↗ |